Landscapes / Companies

GE Healthcare not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
3 approved
2 in Phase 3
Next date
Regadenoson, Phase 1/2 trial completes
Drugs
5
in active trials · 17 in all
Trials
5 active
17 since 2021

Drugs5

DrugHow it worksPartnerStageNext dateDetails
Regadenosonnot checked
Adenosine receptor agonist
Astellas
Approved Dec 2026Phase 1/2 trial completes
—
Approved in the EU 25 Feb 2027Phase 2 trial completes
—
Approved —
—
Phase 2/3 30 Nov 2027Phase 2/3 trial completes
—
Phase 2/3 Jun 2029Phase 2/3 trial completes

About

No active trial
12 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 19 Nov 2026 Industry-sponsored drug trials since 2021

Follow GE Healthcare

Following is part of Solo: you see every change to GE Healthcare the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in